Second Sight Medical Products is part of the medical devices industry and trades as part of the healthcare sector. The company CEO is Jonathan Will Mcguire. Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa.
Previous Intraday Performance:
The EYES shares had a previous change of 1.21% which opened at 0.93 and closed at 0.93. It moved to an intraday high of 0.97 and a low of 0.92.
SeekingAlpha: BBBY and ICPT among premarket losers
Over the last five trading days, EYES shares returned -15.35% and in the past 30 trading days it returned 22.51%. Over three months, it changed 16.39%. In one year it has changed -43.57% and within that year its 52-week high was 2.25 and its 52-week low was 0.64. EYES stock is 46.61% above its 52 Week Low.
Our calculations result in a 200 day moving average of 1.26 and a 50 day moving average of 0.83. Right now, EYES stock is trading -25.87% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Second Sight down 11% premarket on updated Orion data
The company has a market cap of $115.6m with 124.2m shares outstanding and a float of 123.4m shares. Trading volume was 139,610 shares and has experienced an average volume of 376,962 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Second Sight Medical Products was -0.53 which ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.06.
The next earnings report will be: 05-01-2019
The long-term trend of the EPS is a vital number as it helps understand the future potential of Second Sight Medical Products; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -29.30% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 1.30% of insider ownership and 7.20% of institutional ownership.
I calculated the beta to be 2.28
Based on last reported financials, the company’s return on equity is -640.05%, return on assets is -278.76%, price-to-sales is 19.30 and price-to-book is 37.05.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result